Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction
Purpose of Review This narrative review synthesizes sex differences in guideline-directed medical therapy (GDMT) use and response among female patients with heart failure with reduced ejection fraction (HFrEF), discusses female representation in HFrEF clinical trials, and outlines future areas of in...
Gespeichert in:
| Veröffentlicht in: | Current heart failure reports 2021-10, Vol.18 (5), p.284-289 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 289 |
|---|---|
| container_issue | 5 |
| container_start_page | 284 |
| container_title | Current heart failure reports |
| container_volume | 18 |
| creator | Agarwal, Anubha Peters, Sanne A. E. Chandramouli, Chanchal Lam, Carolyn S. P. Figtree, Gemma A. Arnott, Clare |
| description | Purpose of Review
This narrative review synthesizes sex differences in guideline-directed medical therapy (GDMT) use and response among female patients with heart failure with reduced ejection fraction (HFrEF), discusses female representation in HFrEF clinical trials, and outlines future areas of investigation to reduce sex disparities in HFrEF care globally.
Recent Findings
Observational registries suggest sex-specific disparities persist in GDMT rates, and there may be key sex-specific differences in optimal dosing of GDMT in HFrEF patients. Underrepresentation of female patients in HF clinical trials is a key barrier, and sex disparities in HF clinical trial leadership may influence sex-specific knowledge generation of medical management of HFrEF patients.
Summary
There are important sex-specific differences in GDMT use and response among female HFrEF patients that warrant further study. Increasing female representation in HFrEF clinical trials, diversifying HF trial leadership, and embedding sex-specific approaches in the lifecycle of research from conception to reporting are essential to decreasing sex disparities in clinical care of all HFrEF patients. |
| doi_str_mv | 10.1007/s11897-021-00524-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548407187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548407187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-b01ecd0ac8e547c74c279eff918bf82dd1e9ca2633a81da59fdb568a5e61328a3</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EolB4AQ4oRy4B_yW2jwhaQAIhoXK2HHsDrtKk2IlQeXpMUzhy2tHuzEj7IXRG8CXBWFxFQqQSOaYkx7igPP_aQ0ek4GWuCq72_zTDE3Qc4xJjqkSpDtGEcUqYoOoI6bvBO2h8C_mtD2B7cNkTOG9Nky3eIZj1JvNtNoeVaSBmn75_z-7BhD6bG98MAcbVC7jBpuhsmSp8lwLBbMUJOqhNE-F0N6fodT5b3Nznj893DzfXj7llXPR5hQlYh42VUHBhBbdUKKhrRWRVS-ocAWUNLRkzkjhTqNpVRSlNASVhVBo2RRdj7zp0HwPEXq98tNA0poVuiJoWXHIsiBTJSkerDV2MAWq9Dn5lwkYTrH_A6hGsTmD1Fqz-SqHzXf9QrcD9RX5JJgMbDTGd2jcIetkNoU0__1f7DXeghP0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548407187</pqid></control><display><type>article</type><title>Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Agarwal, Anubha ; Peters, Sanne A. E. ; Chandramouli, Chanchal ; Lam, Carolyn S. P. ; Figtree, Gemma A. ; Arnott, Clare</creator><creatorcontrib>Agarwal, Anubha ; Peters, Sanne A. E. ; Chandramouli, Chanchal ; Lam, Carolyn S. P. ; Figtree, Gemma A. ; Arnott, Clare</creatorcontrib><description>Purpose of Review
This narrative review synthesizes sex differences in guideline-directed medical therapy (GDMT) use and response among female patients with heart failure with reduced ejection fraction (HFrEF), discusses female representation in HFrEF clinical trials, and outlines future areas of investigation to reduce sex disparities in HFrEF care globally.
Recent Findings
Observational registries suggest sex-specific disparities persist in GDMT rates, and there may be key sex-specific differences in optimal dosing of GDMT in HFrEF patients. Underrepresentation of female patients in HF clinical trials is a key barrier, and sex disparities in HF clinical trial leadership may influence sex-specific knowledge generation of medical management of HFrEF patients.
Summary
There are important sex-specific differences in GDMT use and response among female HFrEF patients that warrant further study. Increasing female representation in HFrEF clinical trials, diversifying HF trial leadership, and embedding sex-specific approaches in the lifecycle of research from conception to reporting are essential to decreasing sex disparities in clinical care of all HFrEF patients.</description><identifier>ISSN: 1546-9530</identifier><identifier>EISSN: 1546-9549</identifier><identifier>DOI: 10.1007/s11897-021-00524-z</identifier><identifier>PMID: 34213729</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cardiac Surgery ; Cardiology ; Female ; Heart Failure - drug therapy ; Humans ; Imaging ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Radiology ; Registries ; Section Editors ; Sex and Gender Aspects in Heart Failure (G. Figtree and C. Arnott ; Stroke Volume ; Topical Collection on Sex and Gender Aspects in Heart Failure ; Vascular Surgery ; Ventricular Dysfunction, Left</subject><ispartof>Current heart failure reports, 2021-10, Vol.18 (5), p.284-289</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-b01ecd0ac8e547c74c279eff918bf82dd1e9ca2633a81da59fdb568a5e61328a3</citedby><cites>FETCH-LOGICAL-c347t-b01ecd0ac8e547c74c279eff918bf82dd1e9ca2633a81da59fdb568a5e61328a3</cites><orcidid>0000-0002-7090-5601</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11897-021-00524-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11897-021-00524-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34213729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agarwal, Anubha</creatorcontrib><creatorcontrib>Peters, Sanne A. E.</creatorcontrib><creatorcontrib>Chandramouli, Chanchal</creatorcontrib><creatorcontrib>Lam, Carolyn S. P.</creatorcontrib><creatorcontrib>Figtree, Gemma A.</creatorcontrib><creatorcontrib>Arnott, Clare</creatorcontrib><title>Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction</title><title>Current heart failure reports</title><addtitle>Curr Heart Fail Rep</addtitle><addtitle>Curr Heart Fail Rep</addtitle><description>Purpose of Review
This narrative review synthesizes sex differences in guideline-directed medical therapy (GDMT) use and response among female patients with heart failure with reduced ejection fraction (HFrEF), discusses female representation in HFrEF clinical trials, and outlines future areas of investigation to reduce sex disparities in HFrEF care globally.
Recent Findings
Observational registries suggest sex-specific disparities persist in GDMT rates, and there may be key sex-specific differences in optimal dosing of GDMT in HFrEF patients. Underrepresentation of female patients in HF clinical trials is a key barrier, and sex disparities in HF clinical trial leadership may influence sex-specific knowledge generation of medical management of HFrEF patients.
Summary
There are important sex-specific differences in GDMT use and response among female HFrEF patients that warrant further study. Increasing female representation in HFrEF clinical trials, diversifying HF trial leadership, and embedding sex-specific approaches in the lifecycle of research from conception to reporting are essential to decreasing sex disparities in clinical care of all HFrEF patients.</description><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Female</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Radiology</subject><subject>Registries</subject><subject>Section Editors</subject><subject>Sex and Gender Aspects in Heart Failure (G. Figtree and C. Arnott</subject><subject>Stroke Volume</subject><subject>Topical Collection on Sex and Gender Aspects in Heart Failure</subject><subject>Vascular Surgery</subject><subject>Ventricular Dysfunction, Left</subject><issn>1546-9530</issn><issn>1546-9549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OwzAQhC0EolB4AQ4oRy4B_yW2jwhaQAIhoXK2HHsDrtKk2IlQeXpMUzhy2tHuzEj7IXRG8CXBWFxFQqQSOaYkx7igPP_aQ0ek4GWuCq72_zTDE3Qc4xJjqkSpDtGEcUqYoOoI6bvBO2h8C_mtD2B7cNkTOG9Nky3eIZj1JvNtNoeVaSBmn75_z-7BhD6bG98MAcbVC7jBpuhsmSp8lwLBbMUJOqhNE-F0N6fodT5b3Nznj893DzfXj7llXPR5hQlYh42VUHBhBbdUKKhrRWRVS-ocAWUNLRkzkjhTqNpVRSlNASVhVBo2RRdj7zp0HwPEXq98tNA0poVuiJoWXHIsiBTJSkerDV2MAWq9Dn5lwkYTrH_A6hGsTmD1Fqz-SqHzXf9QrcD9RX5JJgMbDTGd2jcIetkNoU0__1f7DXeghP0</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Agarwal, Anubha</creator><creator>Peters, Sanne A. E.</creator><creator>Chandramouli, Chanchal</creator><creator>Lam, Carolyn S. P.</creator><creator>Figtree, Gemma A.</creator><creator>Arnott, Clare</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7090-5601</orcidid></search><sort><creationdate>20211001</creationdate><title>Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction</title><author>Agarwal, Anubha ; Peters, Sanne A. E. ; Chandramouli, Chanchal ; Lam, Carolyn S. P. ; Figtree, Gemma A. ; Arnott, Clare</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-b01ecd0ac8e547c74c279eff918bf82dd1e9ca2633a81da59fdb568a5e61328a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Female</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Radiology</topic><topic>Registries</topic><topic>Section Editors</topic><topic>Sex and Gender Aspects in Heart Failure (G. Figtree and C. Arnott</topic><topic>Stroke Volume</topic><topic>Topical Collection on Sex and Gender Aspects in Heart Failure</topic><topic>Vascular Surgery</topic><topic>Ventricular Dysfunction, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agarwal, Anubha</creatorcontrib><creatorcontrib>Peters, Sanne A. E.</creatorcontrib><creatorcontrib>Chandramouli, Chanchal</creatorcontrib><creatorcontrib>Lam, Carolyn S. P.</creatorcontrib><creatorcontrib>Figtree, Gemma A.</creatorcontrib><creatorcontrib>Arnott, Clare</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current heart failure reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agarwal, Anubha</au><au>Peters, Sanne A. E.</au><au>Chandramouli, Chanchal</au><au>Lam, Carolyn S. P.</au><au>Figtree, Gemma A.</au><au>Arnott, Clare</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction</atitle><jtitle>Current heart failure reports</jtitle><stitle>Curr Heart Fail Rep</stitle><addtitle>Curr Heart Fail Rep</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>18</volume><issue>5</issue><spage>284</spage><epage>289</epage><pages>284-289</pages><issn>1546-9530</issn><eissn>1546-9549</eissn><abstract>Purpose of Review
This narrative review synthesizes sex differences in guideline-directed medical therapy (GDMT) use and response among female patients with heart failure with reduced ejection fraction (HFrEF), discusses female representation in HFrEF clinical trials, and outlines future areas of investigation to reduce sex disparities in HFrEF care globally.
Recent Findings
Observational registries suggest sex-specific disparities persist in GDMT rates, and there may be key sex-specific differences in optimal dosing of GDMT in HFrEF patients. Underrepresentation of female patients in HF clinical trials is a key barrier, and sex disparities in HF clinical trial leadership may influence sex-specific knowledge generation of medical management of HFrEF patients.
Summary
There are important sex-specific differences in GDMT use and response among female HFrEF patients that warrant further study. Increasing female representation in HFrEF clinical trials, diversifying HF trial leadership, and embedding sex-specific approaches in the lifecycle of research from conception to reporting are essential to decreasing sex disparities in clinical care of all HFrEF patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34213729</pmid><doi>10.1007/s11897-021-00524-z</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7090-5601</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1546-9530 |
| ispartof | Current heart failure reports, 2021-10, Vol.18 (5), p.284-289 |
| issn | 1546-9530 1546-9549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2548407187 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Cardiac Surgery Cardiology Female Heart Failure - drug therapy Humans Imaging Internal Medicine Male Medicine Medicine & Public Health Radiology Registries Section Editors Sex and Gender Aspects in Heart Failure (G. Figtree and C. Arnott Stroke Volume Topical Collection on Sex and Gender Aspects in Heart Failure Vascular Surgery Ventricular Dysfunction, Left |
| title | Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A15%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guideline-Directed%20Medical%20Therapy%20in%20Females%20with%20Heart%20Failure%20with%20Reduced%20Ejection%20Fraction&rft.jtitle=Current%20heart%20failure%20reports&rft.au=Agarwal,%20Anubha&rft.date=2021-10-01&rft.volume=18&rft.issue=5&rft.spage=284&rft.epage=289&rft.pages=284-289&rft.issn=1546-9530&rft.eissn=1546-9549&rft_id=info:doi/10.1007/s11897-021-00524-z&rft_dat=%3Cproquest_cross%3E2548407187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548407187&rft_id=info:pmid/34213729&rfr_iscdi=true |